drugset
drugset / Trial / NCT01083589

Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

NCT01083589 ↗

Phase 2 Completed 22 enrolled M.D. Anderson Cancer Center Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn how effective the combination of the drugs imatinib mesylate (Gleevec®) and docetaxel (Taxotere®) is in treating non-small cell lung cancer (NSCLC). The safety and tolerability of this drug combination will also be studied.

Timeline

Start
2005-01
Primary completion
2007-10
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 60 mg/m2 Intravenous
Subject Imatinib Small molecule 400 mg Oral

Indications

non-small cell lung carcinoma